California biotech Apexigen has raised $73 million from a pair of financings that will be used for clinical testing of its lead CD40-targeting immuno-oncology candidate as well as to broaden its pipeline.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,